India Pharma Outlook Team | Wednesday, 22 July 2026
Trump’s new tariff plan has raised fresh concerns for Indian pharma companies that depend on the US market.
US President Donald Trump announced a phased tariff policy for imported generic drugs. The plan offers a two-year relief period before heavy duties take effect.
The announcement has sparked questions about the future of pharmaceutical exports from India. It also puts pressure on companies to rethink their manufacturing strategy.
Trump said imported generic medicines will not face US tariffs for the first two years. After that, a 100% tariff will apply for one year. The duty will then increase to 200%.
The announcement is part of Trump's broader effort to boost drug manufacturing inside the United States. He wants more pharmaceutical companies to produce medicines within the country instead of importing them.
The two-year window gives companies time to adjust. Businesses can review their supply chains and decide their next steps before the higher tariffs begin.
India is the largest supplier of generic medicines to the United States. Many leading drugmakers earn a large share of their revenue from the US market. The proposed tariffs could make Indian medicines more expensive for American buyers. Companies may have to absorb higher costs or shift production to the US.
Several Indian pharmaceutical firms already have manufacturing facilities in America. Others may now consider expanding their presence to avoid future tariffs. The announcement also affected investor sentiment. Shares of major drug companies declined after the news. Investors fear the policy could hurt long-term earnings if companies fail to adapt.
Also Read: The Strategic Role of Regional Corridors in Future-Ready MedTech
The tariff announcement does not have an immediate financial impact because of the two-year exemption. However, it gives companies a limited window to prepare.
Drugmakers with strong US exposure are expected to evaluate fresh investments. Some may increase local manufacturing in America. Others could diversify into new export markets to reduce dependence on the US.
Industry experts believe the next two years will be critical. Companies that act early may reduce the impact of future tariffs. Those that delay could face higher costs once the duties come into force.
The final impact will depend on how the policy is implemented. It will also depend on how quickly pharmaceutical companies respond. For now, Indian drugmakers have time to plan, but the countdown has already begun.
